Page 110 - 2018_09-Mondo

P.M. Barr et al.
Bruton tyrosine kinase inhibitor PCI-32765
thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-1189.
9. Spaargaren M, Beuling EA, Rurup ML, et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med. 2003;198(10):1539-1550.
10. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
11. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lym- phoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.
12. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-2506.
13. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.
14. Ibrutinib [package insert]. Sunnyvale, CA; Pharmacyclics LLC; 2017.
15. Ibrutinib [summary of product characteris- tics]. Beerse, Belgium; Janssen-Cilag International NV; 2017.
16. Coutre S, Tedeschi A, Robak T, et al. Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lympho- cytic leukemia/small lymphocytic lym- phoma. Haematologica. 2017 Nov 23. [Epub ahead of print].
17. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on
Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111 (12):5446-5456.
18. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Chronic lymphocytic leukemia/small lymphocytic leukemia. National Comprehensive Cancer Network; 2016. Available from: https://www.nccn.org/professionals/physi- cian_gls/default.aspx#site. Accessed January 11, 2018.
19. O'Brien PC, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy in patient with CLL: Analyses from phase III data. J Clin Oncol. 2016;34(suppl). Abstract 7520.
20. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal muta- tions in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
21. Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM muta- tions in chronic lymphocytic leukemia. Blood. 2016;127(17):2122-2130.
22. O'Brien SM, Furman RR, Coutre SE, et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128(22):233-233.
23. Parikh SA, Rabe KG, Kay NE, et al. Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014; 99(1):140-147.
24. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chron- ic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
25. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and
cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376 (9747):1164-1174.
26. Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.
27. Kipps TJ, Fraser G, Coutre SE, et al. Outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) with high-risk prognostic factors in an integrated analysis of 3 randomized phase 3 studies. Abstract presented at: the XVII International Workshop on Chronic Lymphocytic Leukemia; May 12-15, 2017; New York, NY. Abstract 19.
28. Brown JR, Moslehi J, O'Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib ran- domized controlled registration trials. Haematologica. 2017;102(10):1796-1805.
29. Holtzer-Goor KM, Schaafsma MR, Joosten P, et al. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multi- centre study. Qual Life Res. 2015;24(12): 2895-2906.
30. Jain P, Thompson PA, Keating M, et al. Long- term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268-2273.
31. Mato AR, Nabhan C, Barr PM, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18): 2199-2205.
32. Mato AR, Hill BT, Lamanna N,et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017; 28(5):1050-1056.
1510
haematologica | 2018; 103(9)